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Abstract
Metabolic reprogramming is considered a hallmark of cancer. Currently, the altered lipid
metabolism in cancer is a topic of interest due to the prominent role of lipids regulating the
progression of various types of tumors. Lipids and lipid-derived molecules have been shown
to activate growth regulatory pathways and to promote malignancy in pancreatic cancer. In
a previous work, we have described the antitumoral properties of Yarrow (Achillea Millefo-
lium) CO2 supercritical extract (Yarrow SFE) in pancreatic cancer. Herein, we aim to investi-
gate the underlaying molecular mechanisms by which Yarrow SFE induces cytotoxicity in
pancreatic cancer cells. Yarrow SFE downregulates SREBF1 and downstream molecular
targets of this transcription factor, such as fatty acid synthase (FASN) and stearoyl-CoA
desaturase (SCD). Importantly, we demonstrate the in vivo effect of Yarrow SFE diminishing
the tumor growth in a xenograft mouse model of pancreatic cancer. Our data suggest that
Yarrow SFE can be proposed as a complementary adjuvant or nutritional supplement in
pancreatic cancer therapy.
Introduction
Pancreatic cancer is the second leading cause of cancer-related deaths worldwide. It is an
aggressive malignancy with poor prognosis: the overall 5-year survival rate is less than 5%.
Risk factors described to be linked with its development are obesity and chronic pancreatitis,
but also tobacco smoking, heavy alcohol intake, unbalanced diets, or high red meat intake
[1,2]. Given the absence of indicators of illness, it is often diagnosed at metastatic late stages.
Although surgery remains the main beneficial treatment followed by chemotherapy and radia-
tion, current therapies do not improve patient’s survival. Therefore, the development of effec-
tive therapeutic strategies targeting molecular alterations associated with pancreatic tumor
growth and the resistance to apoptosis are needed to improve their survival.
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In the last years, there has been a growing interest in the use of phytochemicals and dietary-
derived compounds for prevention or for cancer treatment [3,4]. Thus, some of them have
shown antitumoral properties in vitro and in vivo [4–6]. In this regard, there are some phyto-
chemicals derived from natural sources, such as taxol and camptothecin, which are extensively
used in clinics to treat several tumors [7,8]. Nevertheless, pancreatic cancer remains one of the
most resistant tumor [9]. Current chemotherapy is based on the use of gemcitabine, 5-fluoro-
uracil, irinotecan and/or oxaliplatin but new complementary approaches are required.
On the other hand, metabolic reprogramming is well-recognized as a hallmark of cancer
[10] and thus, there is an increased interest for targeting its altered metabolism. Tumors display
high rates of cell proliferation and they can acquire malignancy associated to stemness and inva-
sive properties. Moreover, highly proliferative cells hold an exacerbated glucose uptake sustain-
ing aerobic glycolysis (Warburg effect) for anabolic processes [11–13]. In addition, increased
glutamine uptake and glutaminolysis support carbon and nitrogen backbones for anabolic pur-
poses. Nitrogen, in addition to its role in protein and nucleotide biosynthesis, is crucial for the
synthesis of glutathione and essential to maintain the redox homeostasis [12–14].
Cancer cells are also characterized by having an increased de novo fatty acid synthesis
which contributes to the carcinogenic process and cancer cell survival. Metabolic fatty acid
(FA) enzymes are essential for neoplastic growth as well as for the signaling of key tumorigenic
pathways. During tumor development, lipid associated alterations include an increase in lipo-
genic enzymes expression such as fatty acid synthase (FASN), acetyl carboxylase (ACC), stear-
oyl-CoA desaturase (SCD), ATP citrate lyase (ACLY), and an increase in the synthesis and
uptake of cholesterol. As a result, tumor cells can control membrane fluidity, which has an
impact on intracellular oncogenic signaling pathways, and sharpens resistance to chemothera-
peutics. In addition, the increased storage of lipid and cholesterol molecules into lipid droplets
allows tumor cells to gain independence from the extracellular nutrient availability [15,16].
In this context, many authors have described alterations in expression of lipid metabolic
genes, and their link with the development and prognosis in cancer [17,18]. Thus, targeting
specific enzymes involved in fatty acid and cholesterol synthesis, or affecting genes involved in
their transcriptional regulation could be a novel approach for cancer treatment [19,20].
Recently we have described the antitumoral properties of Achillea Millefolium derived
extract, commonly known as Yarrow, obtained by Supercritical Fluid Technology (SFE), in
pancreatic cancer cell lines [21]. Yarrow SFE diminishes cell viability of pancreatic cancer cells
in a dose dependent manner, induces apoptosis and inhibits anchorage independent cell
growth. Moreover, Yarrow SFE synergizes with 5-fluororacil (5-Fu) which is currently used in
the clinics in pancreatic cancer treatment [22]. Herein, we identify Sterol Regulatory Element-
Binding Transcription Factor 1 (SREBF1) as a molecular target of Yarrow SFE which is impli-
cated, at least partially, in the antitumoral activities observed. Importantly, downstream molec-
ular targets of SREBP1, such as FASN and SCD, are also diminished both at the transcriptional
and post-transcriptional levels. These alterations would affect intracellular lipid homeostasis
which also correlate with the inhibition of invasiveness properties of pancreatic cancer cells.
Importantly, we also demonstrate the in vivo effect of Yarrow SFE diminishing the tumor
growth in a xenograft model of pancreatic cancer. Based on these results, Yarrow supercritical
extract could be proposed as a complementary adjuvant in pancreatic cancer therapy.
Methods
Yarrow extract
Yarrow SFE was obtained by CO2 supercritical fluid extraction (Thar Technology, model
SF2000). Briefly, a CO2 flux of 70 g/min, 140 bar and 40˚C for 180 minutes was applied to 400
Yarrow extract as a supplement in pancreatic cancer
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g of dried and grounded Yarrow in a 2L cylinder. The resulting extract was collected with
absolute ethanol, and the dissolvent was removed using a rotavapor at low temperature
(30˚C).
The extract contains volatile oils which comprises monoterpenes such as eudesmol
(11.19%) and borneol (16.28%) as major compounds, and sesquiterpenes as caryophyllene
(4.90%), α-cadinol (8.22%), α-bisabolol (2.73%), among others [21].
Cell culture
Pancreatic cancer cells MIA PaCa-2 and PANC-1 were purchased from American Type Cul-
ture Collection (Manassas, VA) and were cultured in DMEM media (2 mM glutamine) and
10% fetal bovine serum (LONZA Iberica, S.A) in 5% CO2 atmosphere at 37˚C and 95% humid-
ity. 5 x 106 cells were seeded in M6 multiwell plates for microarray assays and in a p60 culture
dishes to isolate proteins for WB analysis and mRNA for qPCR.
RNA isolation and gene expression assay
MIA Paca-2 and PANC-1 cells were plated and after an overnight incubation, cells were
treated with 30 and 70 μg/mL of Yarrow extract for 48 hours. Non-treated cells were kept as
controls. Total RNA was isolated from each condition with RNeasy Mini Kit (Qiagen Iberica)
following manufacturer´s instructions. RNA quality and quantity were checked by UV spec-
troscopy (Nanodrop 2000 Spectrophotometer, Thermo Scientific, Waltham).
RNA extracted from MIA PaCa-2 was subsequently used for a comparative microarray
gene expression analysis between non-treated and 30 and 70 μg/mL Yarrow treated cells. The
analysis was performed at the Genomic Service Facilities at the National Center of Biotechnol-
ogy (CNB-Madrid, Spain). RNA integrity was first determined using a 2100 Bioanalyzer (Agi-
lent Technologies, Santa Clara, CA). RNAs were then reverse transcribed and fluorescently
tagged using the one color Low Input Quick Amp Labeling Kit (Agilent Technologies), accord-
ing to manufacturer’s instructions. The complementary RNAs were hybridized in an Agilent
Sure Print G3 Human 8x60 K (Whole Human Genome Microarray Kit) platform, using the
one-color gene expression system as described by the manufacturer (Agilent Technologies).
Quantitative real-time polymerase chain reaction (qPCR)
Same amounts for each RNAs samples were reverse transcribed by a high Capacity cDNA
Archive Kit (applied Biosystems) for 2 hours at 37˚C. To determine gene expression, Real-
time-qPCRs were performed on the 7900HT-Real-Time PCR System (Applied Biosystems,
Foster City, CA) using the TaqMan gene expression assays. The probe sets were Hs01005622,
Hs01682761, Hs01088691, Hs00607129, Hs 1597989, Hs99999901_s1 for FASN, SCD,
SREBF1, HSPA-5, ASS1 and 18s, respectively. For the isoforms SREBP1-a and SREBP1-c, the
primers used to quantify their expression were hSREBP-1a (Fw: GGAGGGGTAGGGCCAACGG
CCT; Rv: CATGTCTTCGAAAGTGCAATCC) and hSREBP-1c (Fw: TCAGCGAGGCGGCTTTGG
AGCAG; Rv: CATGTCTTCGATGTCGGTCAG). The relative expression quantity for each gene
(RQ) was determined following the 2-ΔΔCt Livak method [23].
RQ Manager Software and Expression Suite Software (Applied Biosystems) were used to
calculate the relative expression of each gene.
Intracellular cholesterol and neutral lipid content
To determine the total intracellular cholesterol, the assay was carried out following the instruc-
tions of Cholesterol Detection Kit (cell-based) (BioVision Inc, San Francisco, USA). Briefly,
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cells were cultured with 50 and 70 μg/mL Yarrow for 48 hours before to be extracted with
200 μL of chloroform: Isopropanol: NP-40 (7:11:0.1) in a micro-homogenizer. The lipid frac-
tion was collected and mingled with a cholesterol enzyme mix (which includes cholesterol
esterase), and the absorbance of the resultant colorimetric assay was measured at 570 nm.
Quantification of neutral lipid content was done by mean of Bodipy staining. As a brief
description, cells were treated with 2 μM BODIPY staining solution (BODIPY 493/503, Invi-
trogen) in PBS for 15 min at 37˚C and fixed with 4% paraformaldehyde (PFA). Images were
obtained with a Leica DM IL microscope, 40X Plan Fluotar objective and registered using
Leica Application Suite (LAS).
Immunoblot analysis
After 48 hours incubation with Yarrow SFE, cells were washed and detached using trypsin.
Protein lysates were obtained with Laemmli buffer (60 mM Tris-HCl, 10% glycerol 2% SDS)
and centrifuged at 5000 rpm for 5 minutes. After quantification (BCA-Piercing), denaturalized
protein samples were separated through a 4–15% Mini-Protean TGX Precast Protein Gel
(BioRad) and transferred onto a nitrocellulose membrane using Trans-Blot Turbo Transfer
System (BioRad). Membranes were incubated in 5% non-fat dried milk PBS (1% Tween-20) at
room temperature for 1 hour and then incubated overnight with primary antibodies against
FASN (Cell Signaling) and SCD (kindly provided by Dr Demoulin [24]. α-tubulin (Sigma-
Aldrich) was used as a loading control.
Invasion through matrigel
To evaluate the effect of Yarrow SFE on invasiveness, MIA PaCa-2 cells were treated for 48
hours with different doses of Yarrow SFE. After discarding dead cells, a total of 2.2×104 alive
ones were then maintained in 1% FBS DMEM (without extract) and seeded onto Matrigel-
coated Transwell chambers) (8.0 μm pore) (Corning Life Sciences). In the lower chamber,
700 μL of DMEM with 10% FBS were added as a chemo attractant. 48 hours later, inserts were
washed twice with PBS and fixed with 4% paraformaldehyde prior to crystal violet staining.
Cells that have invaded through Matrigel in four random fields were counted using a light
microscope at ×10 magnification.
Animals and tumor xenograft model
All procedures were approved by the Animal Care and Use Committee of the Consejo Supe-
rior de Investigaciones Cientı´ficas (CSIC, Spain), and by the authority of the Comunidad of
Madrid (PROEX112/17). Male Hsd: Athymic Nude-Foxn1nu nude mice (7 weeks old, weigh-
ing 26–31 g) were purchased from Envigo RMS (Spain). Mice were kept in a temperature and
humidity-controlled environment, with 12 hours light/dark-cycle and had access to water and
standard chow (Safe, D40 RMM. Proteins 15.2%, Fat: 3.2%, Minerals Ash: 4.4%, Fiber: 4.1%)
ad libitum.
The xenograft model was obtained by injecting subcutaneously into the back loin 1,5 x106
MIA PaCa-2 cells diluted in DMEM: Matrigel (50:50). After 15 days, 8 animals received Yar-
row SFE extract (1000 mg/Kg), diluted in corn oil (Sigma-Aldrich) in 150 μL as final volume.
The treatment was administrated using an orogastric silicon-tube, three times per week for 15
days. Intragastrical administration of an equal volume of corn oil alone was given to 8 control
animals.
Human endpoints were established if tumors had reached 1.6 cm3 or more, or if there had
been signs of ulceration, or mice had lost 20% or more of body weight, or if mice had pre-
sented piloerection, stereotyped or aggressive behaviors, pain indicative postures, lack of
Yarrow extract as a supplement in pancreatic cancer
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activity and tremors or convulsions. Animals were daily monitored, assessing the room tem-
perature and humidity, and their health by checking their behavior and general appearance.
Body weight was measured weekly. The antitumor effect of Yarrow was monitored by estimat-
ing tumor volume (mm3) and calculated as (W2 x L) x 0.52, where W is tumor width (in mm)
and L is tumor length (in mm).
Finally, animals were euthanized by cervical dislocation.
Immunohistochemistry
Immunohistochemistry was performed following standard protocols. Mouse monoclonal anti-
body against Ki-67 (IR626, DAKO) was used on tissue paraffin sections (4μm). Images were
obtained through the Axio Scan Z1 (Zeiss). The quantification of Ki-67 positive cells was done
with ZEN Lite 2.3 software (Zeiss).
Statistical analysis
Microarray gene expression data were obtained and analyzed using FIESTA software (version
1.0, http://bioinfogp.cnb.csic.es/tools/FIESTA; Centro Nacional de Biotecnologı´a, Madrid,
Spain). Statistical analyses were determined by the Limma package (linear models for microar-
ray data) (Smyth, 2004), using a p-value<0.05 as limit of significance. Overexpression and
repression were considered from a minimum change of 2-fold of the non-treated cells
(control).
RT-qPCR results were analyzed by using two-way ANOVA (Bonferroni post hoc test).
Western Blot results were quantified by Image J and statistically analyzed by one-way ANOVA
(Bonferroni post hoc test). One-way ANOVA was also used to determine differences in inva-
sion and 3D-culture. Results of in vivo experiments were analyzed with t-student statistical
analysis. Statistical differences were considered significant when p-value was <0,05.
All the statistical analysis was performed with GraphPad Prim 6 statistical software.
Results
Yarrow SFE downregulates the expression of the lipid metabolism-master
regulator SREBF1
In a previous work we have described that Yarrow SFE inhibits cell viability of MIA PaCa-2
and PANC-1 pancreatic cancer cell lines, with an induction of apoptotic cell death [22].
In order to identify the molecular targets implicated on the mechanism of action of Yarrow
SFE, a comparative gene expression microarray (G2519F-026652 Human Gene Expression v2
4x44K Microarray) was performed (link to raw data: https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE124043). MIA PaCa-2 cells were treated with two different doses of
Yarrow (IC50: 31,45 ±8,56 μg/mL and 2x IC50) for 48 hours. Genes whose expression was sig-
nificantly altered at both concentrations (p-value<0.05), with a minimum of 2-fold change
overexpression or repression, compared to control non-treated cells (DMSO), are listed in
Table 1.
SREBF1 (Sterol Regulatory Element Binding Transcription Factor), ASS1 (Argininosucci-
nate Synthase) and HSPA-5 (Homo Sapiens Heat Shock protein 5) were selected for further
validation by RT-qPCR due to their known association with tumor processes and with pancre-
atic cancer development. As shown in Fig 1, Yarrow SFE significantly diminished the expres-
sion levels of SREBF1 in a 25% and 48% after 30 and 70 μg/m treatments respectively,
compared to control cells (DMSO).
Yarrow extract as a supplement in pancreatic cancer
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Sterol regulatory element binding proteins (SREBP) are master transcriptional regulators of
the synthesis and uptake of lipids and cholesterol [80]. In mammals, there are two isoforms of
SREBP proteins, SREBP1 and SREBP2. SREBP1 is mainly implicated in the expression of
genes for de novo synthesis of fatty acids, meanwhile SREBP2 is dedicated to the regulation of
genes involved in the synthesis and uptake of cholesterol. Nevertheless, SREBP1 and 2 signifi-
cantly overlap in the regulation of lipid homeostasis [81,82].
SREBP1 has been found highly upregulated in several cancers. In humans, it includes, in
turn, two isoforms: SREBP1c which regulates FA metabolism, and SREBP1a which is impli-
cated in both fatty acid (FA) and cholesterol metabolism [81].
Table 1. Microarray data of differentially expressed genes after treatment of MIA PaCa-2 pancreatic cancer cell line with 30 and 70 μg/mL Yarrow for 48 hours.
Data represent the value of the most significant probe for three independent experiments for each condition. Genes with a statistical significant difference (p-value< 0,05)
and more than 2-fold absolute change variation compared to control (DMSO) are shown.
Yarrow (μg/
mL)
Genes Fold
Change
P-value
(Limma)
Systematic
Name
Description Cancer
Ref.
Pancreatic Cancer
Ref.
30 ASS1 -3,62 0,033 NM_000050 Homo sapiens argininosuccinate synthase 1, transcript
variant 1
[25–27] [28–30]
70 -4,38 0,0477
30 CHD5 2,84 0,0036 NM_015557 Homo sapiens chromodomain helicase DNA binding
protein 5
[31–33] [34]
70 2,40 0,0026
30 CREBZF 2,82 0,0017 NM_001039618 Homo sapiens CREB/ATF bZIP transcription factor,
transcript variant 1
[35,36]
70 2,08 0,0214
30 CSTF3 2,08 0,0355 NM_001033505 Homo sapiens cleavage stimulation factor, transcript
variant 2
[37,38]
70 2,08 0,0269
30 DHRS3 -2,78 0,0178 NM_004753 Homo sapiens dehydrogenase /reductase (SDR family)
member 3
[39,40]
70 -2,52 0,0435
30 HLA-G -2,80 0,0415 NM_002127 Homo sapiens major histocompatibility complex, class I, G [41–43] [44,45]
70 -3,58 0,0280
30 HSPA5 -2,44 0,0406 NM_005347 Homo sapiens heat shock 70kDa protein 5 glucose-
regulated protein,78kDa
[46–49] [50–52]
70 -2,51 0,0444
30 ICAM5 -2,05 0,0145 NM_003259 Homo sapiens intercellular adhesion molecule 5,
telencephalin
[53,54]
70 -2,02 0,0196
30 ING3 2,44 0,0035 NM_019071 Homo sapiens inhibitor of growth family, member 3
transcript variant 1
[55,56]
70 2,03 0,0152
30 MEF2D -2,98 0,0144 NM_005920 Homo sapiens myocyte enhancer factor 2D, transcript
variant 1
[57–59]
70 -2,18 0,0155
30 PALM -3,21 0,0028 NM_002579 Homo sapiens paralemmin, transcript variant 1 [60,61]
70 -2,09 0,0271
30 RAB11FIP1 -2,06 0,0334 NM_001002814 Homo sapiens RAB11 family interacting protein 1 (class I),
transcript variant 3
[62]
70 -2,11 0,0448
30 SERPINA3 -3,01 0,0078 NM_001085 Homo sapiens serpin peptidase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin), member 3
[63,64]
70 -2,27 0,0061
30 SHC1 -2,21 0,0237 NM_003029 Homo sapiens SHC (Src homology 2 domain
containing) transforming protein 1, transcript
variant 2
[65] [66]
70 -2,01 0,0359
30 SKAP2 -2,61 0,0149 ENST00000345317 Src kinase associated phosphoprotein 2 [67,68] [69]
70 -2,08 0,0346
30 SREBF1 -2,75 0,0004 NM_001005291 Homo sapiens sterol regulatory element binding
transcription factor 1, transcript variant 1
[70–74] [75,76]
70 -2,05 0,0064
30 TRIM44 -2,13 0,0351 NM_017583 Homo sapiens tripartite motif containing 44 [77–79]
70 -2,07 0,0371
https://doi.org/10.1371/journal.pone.0214294.t001
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As individual functions of SREBPs are overlapped, we wanted to determine the effect of
Yarrow SFE on the expression of the two SREBP1 isoforms. As shown in Fig 2A, RT-qPCR
analysis showed that Yarrow SFE diminished the expression of SREBF1a and 1c similarly in a
dose-dependent manner.
On the other hand, the altered cholesterol homeostasis is frequently linked to the tumori-
genic process and malignancy of tumors [83]. Considering that SREBP1a and SREBP2 share
around 45% of homology at the protein level, we wonder if Yarrow SFE extract could affect the
expression of SREBF2 in a similar manner it does with SREBF1. Treatments with Yarrow SFE
did not show a significant affectation of the expression levels of SREBF2 neither in MIA PaCa-
2 (Fig 2B) nor in PANC-1 (Fig 2C). Indeed, when we analyzed the intracellular cholesterol
content, we did not found differences between Yarrow SFE treatments compared to control
cells (S1 Fig), certainly due to the non-alteration of SREBP2 expression.
These results suggest that SREBP2 can maintain the cholesterol homeostasis in spite of the
downregulation of SREBP1, where Yarrow SFE specifically targets the expression of SREBF1
transcription factor.
Importantly, as the activity of SREBP1 is low in normal tissues and aberrantly increased in
cancer pathogenesis [84], its inhibition has been considered a promising strategy for cancer
treatment [75,82].
Yarrow SFE downregulates FASN and SCD downstream molecular targets
of SREBP1
Multiple studies have revealed that oncogenic pathways such as PI3K/Akt signaling, which reg-
ulates glucose metabolism, and oncogenic Myc, which regulates glutamine metabolism, end
up with the upregulation of SREBP1 to promote fatty acid synthesis [84–86].
Thus, SREBP1 connects oncogenic upregulation of glycolysis and/or glutaminolysis to lipo-
genesis [11], by inducing the expression of Fatty Acid Synthase (FASN) and the Stearoyl-CoA
desaturase (SCD), among others. As we did not have observed any significant difference
Fig 1. Microarray validation. mRNA relative expression in human pancreatic cancer-derived cells (MIA PaCa-2) treated with
two different concentrations of Yarrow extract (30 and 70 μg/mL) in comparison with non-treated cells (subtracting the
endogenous control 18S ribosomal RNA). Data represent the mean ± S.E.M of three independent experiments each one
performed in triplicate. Asterisks indicate statistical differences in treated cells in comparison with the control (DMSO)
�p<0.05.
https://doi.org/10.1371/journal.pone.0214294.g001
Yarrow extract as a supplement in pancreatic cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0214294 March 26, 2019 7 / 21
regardless cholesterol levels, we wonder if lipogenic genes regulated by SREBP1, such as FASN
and SCD, could be altered. Yarrow SFE treatments of MIA PaCa-2 cells for 48 hours downre-
gulated the expression levels of FASN and SCD enzymes, both at the transcriptional (Fig 3A)
and at the post-transcriptional levels (Fig 4A).
We obtained similar results after Yarrow SFE treatment in PANC-1, a pancreatic cancer
cell line which has been described to be more chemo and radio-resistant, compared to MIA
PaCa-2 cells [87,88]. Fig 3B shows a significant downregulation of the mRNA expression levels
of SREBP1, FASN and SCD in PANC-1 pancreatic cancer cell line, and Fig 4B shows a ten-
dency towards a reduction in the protein expression levels of FASN and SCD.
Fig 2. Yarrow SFE inhibits the expression of SREBP1 but not the expression of SREBP2. (A) Expression levels of SREBF1a and SREBF1c isoforms, (B) and
levels of SREBF2 mRNA relative expression in human pancreatic cancer-derived MIA PaCa-2 (C) and PANC-1 cells treated 48 hours with different
concentrations of Yarrow SFE. Data represent the mean ± S.E.M of three independent experiments each one performed in triplicate. Asterisks indicate
statistical differences in treated cells in comparison with control (DMSO) and �p<0.05; ��p<0.01.
https://doi.org/10.1371/journal.pone.0214294.g002
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The effect of Yarrow SFE on SREBF1 downregulation seems to be highly specific, as similar
results were obtained in other cancer types, such as in SW-620, a colon cancer cell line (S2
Fig).
Yarrow SFE diminishes intracellular lipid content and cell invasion
Tumor cell invasion is an important read-out of the aggressiveness and metastatic potential of
cancer cells. In this regard, it has been described a link between FASN downregulation and the
reduction of invasion in cancer [84,89]. Thus, next we aimed to investigate the ability of Yar-
row SFE to affect the invasion capabilities of MIA PaCa-2 cells through Matrigel-coated cham-
bers. After 48 hours of exposition to Yarrow SFE extract, cells which still alive were placed
onto a Matrigel chamber and those invading the matrix towards the lower chamber were mon-
itored. Yarrow SFE treatment significantly reduced the number of cells that passed through
Matrigel in a dose-dependent manner, with a reduction of the invading cells of a 50% and 80%
after treatment with 30 and 70 μg/mL of the extract, respectively, compared to control non-
treated cells (DMSO) (Fig 5A). To further assess the impact of Yarrow SFE in intracellular
lipid metabolism, we used the Bodipy fluorophore, a specific dye for cellular neutral lipid drop-
lets content. As shown in Fig 5B, MiaPaca-2 treated cells with Yarrow SFE were less prone to
neutral lipid droplets accumulation compared to control non-treated cells (DMSO). These
results suggest that alterations in lipid homeostasis impact on signaling pathways implicated in
invasion.
Yarrow-SFE inhibits the growth of pancreatic tumor xenografts in athymic
nude mice
As we have previously shown in vitro, antitumoral effects of Yarrow SFE on pancreatic cancer
cells reduce cell viability, inhibit tridimensional cell growth, and induce apoptosis [22]. As
here we found an inhibition of invasion and a reduced expression of molecular targets impli-
cated in FA and cholesterol homeostasis, we aimed to investigate whether Yarrow SFE could
inhibit in vivo the tumor growth of pancreatic cancer cells using a xenograft mouse model.
With this purpose, we injected 1,5x106 of MIA PaCa-2 cells subcutaneously in nude mice.
Tumor volume was measured three times per week from the day of inoculation. When tumors
reached an average volume of 100 mm3, mice were treated with 1000 mg/kg Yarrow 3 times
per week. As shown in Fig 6A, tumor growth was reduced in Yarrow SFE treated animals
compared to control animals (corn oil) being statistically significant after 10 days of treatment.
Tumor weights at the end of the experiment showed significant reduced values in Yarrow
SFE treated mice compared to control animals (Fig 6B). Importantly, we did not find differ-
ences regardless body weights nor liver weights (Fig 6C and 6D).
At the end of the experiment, Yarrow SFE treated mice presented a tumor volume reduc-
tion of 28.69% (P < 0.05) compared to the control ones (corn oil). Ki-67 staining showed a
decrease in the number of Ki-67 positive cells in the tumors of Yarrow SFE treated mice com-
pared to control ones, indicating a reduction in proliferation of tumor cells (Fig 7A). Impor-
tantly, the expression levels of SREBF1 in the tumors of Yarrow SFE treated animals was also
significantly reduced compared to control animals (Fig 7B).
Discussion
Pancreatic cancer remains one of the most uncontrollable and devastating malignant tumors
due to its late diagnosis and chemo-refractory profile.
The altered metabolism in tumoral cells has been highlighted in the last years, being an
important part of the metabolic reprogramming found in cancer. Lipids, in addition to their
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role as fuels for ATP production, they play a key role as components of plasmatic and organ-
elles membranes, affecting their plasticity, and are also important as cell signaling molecules.
Lipid metabolism alterations have been related to an increase in tumor progression and malig-
nancy. In this regard, SREBP proteins, which are master regulators of lipid metabolism,
together with FASN and SCD have been found to be upregulated in several neoplasia.
Fig 3. Yarrow SFE inhibits the expression levels of SREBP1 molecular targets FASN and SCD in MIA PaCa-2 and PANC-1 pancreatic cancer cells. (A)
mRNA relative expression in human pancreatic cancer-derived MIA PaCa-2 and (B) PANC-1 cells treated 48 hours with different concentrations of Yarrow
extract. Data represent the mean ± S.E.M of three independent experiments each one performed in triplicate. Asterisks indicate statistical differences in treated
cells compared to control (DMSO) and ���p<0.001; ����p<0.0001.
https://doi.org/10.1371/journal.pone.0214294.g003
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Regardless pancreatic cancer, alterations in lipid metabolism have been also described, such as
the increase of de novo lipogenesis, which supports tumor growth and malignancy [75,84] and
correlates with poorer prognosis in clinics [90].
In this scenario, new approaches to target the altered lipid metabolism in cancer are
required to improve cancer patient´s survival. Plant-derived products are a source of bioactive
compounds with a reduced toxicity that have great potential in the treatment of chronic dis-
eases conditions including obesity, metabolic syndrome, type 2 diabetes, cardiovascular dis-
eases and cancer [91,92]. Conventional strategies of pharmaceutical industries are focused on
isolating pure components as a treatment approach, but plant derived extracts are of great
interest because they are composed by several bioactive phytochemicals, as well as because
they can act synergistically and target several genes.
In this context, we recently have investigated the antitumoral properties of Yarrow SFE
extract (obtained by supercritical fluid extraction -SFE-). Yarrow SFE diminished cell viability
of pancreatic cancer cell lines by induction of apoptosis. Moreover, it reduced the ability of
these cells to growth and to form colonies in Matrigel. Importantly, Yarrow SFE extract syner-
gized with the antimetabolite 5-fluororacil which is currently used in clinics to treat pancreatic
tumors, making the treatment more effective [22].
Herein, by microarray gene expression analysis of MIA PaCa-2 cells treated with Yarrow
SFE (at 30 and 70 μg/mL), we identify SREBF1 transcription factor as a direct molecular target
Fig 4. Yarrow SFE extract diminishes FASN and SCD protein levels in MIA PaCa-2 and PANC-1 pancreatic cancer cels. (A) Western blot protein analysis
and quantification of FASN and SCD in MIA PaCa-2 and (B) in PANC-1 cell lines treated with Yarrow SFE extracts for 48 hours. Bar data represents the
mean ± S.E.M of three independent experiments each one performed in duplicate, and bands are representative of one experiment. Asterisks indicate statistical
differences in treated compared to non-treated cells �p<0.05; ���p<0.001.
https://doi.org/10.1371/journal.pone.0214294.g004
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of the extract. The same tendency is found in another pancreatic cancer cell line, PANC-1,
which is has been reported to be a more aggressive [93]. Yarrow SFE targets similarly SREBF1a
and SREBF1c isoforms, but do not significantly downregulates the expression of SREBF2.
SREBP1c binds to the promoter of genes such as FASN (Fatty Acid Synthase), SCD (Stear-
oyl-CoA Desaturase) or ACC (Acetyl-CoA carboxylase) [94–96], which are essential players
for de novo synthesis of fatty acids or lipogenesis.
In pancreatic cancer, it has been shown that SREBP1 expression is significantly higher in
tumoral tissue compared to adjacent normal tissue. In addition, the aberrant expression of this
gene predicts worst prognosis [75]. SREBP1 levels are also increased in other types of cancer,
such as prostate, liver, or endometrial tumors, conferring them higher invasion and metastatic
capacities [70,73,74]. Thus, SREBP1 has been proposed by several authors as a potential thera-
peutic target in cancer treatment [82]. In pancreatic cancer cells (PANC-1, PxPC3 and
SW1990), SREBP1 silencing reduced proliferation and colony formation. Moreover, SREBF1
Fig 5. Yarrow SFE extract reduces MIA PaCa-2 cell invasion and intracellular neutral lipid content. (A) Quantification of cells invading through Matrigel-coated
chambers after 48h of treatment with Yarrow SFE compared to non-treated control cells (DMSO). Data represent mean ± S.E.M of three independent experiments each
one performed in duplicate. (B) Representative immunofluorescence images of the fluorophore Bodipy distribution in MIA PaCa-2 treated cells with Yarrow SFE and
non-treated cells, carried out twice. Asterisks indicate statistical differences between Yarrow SFE treated cells compared to non-treated cells (��p<0,01; ���p<0.001;
����p<0.001).
https://doi.org/10.1371/journal.pone.0214294.g005
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silencing diminished the expression of key growth- and apoptosis-regulating genes such as
FASN, SCD, TP53, ACC, that results in the decrease of intracellular lipid content and apopto-
sis [97]. These results are similar to ours after Yarrow SFE treatments, where there is a reduc-
tion of SREBF1 expression levels together with an inhibition of invasion and induction of
apoptosis (caspase activation). In addition, we have previously shown that Yarrow SFE is more
selective against cancer cell lines than normal cells [22]. As cancer cells present higher expres-
sion of SREBF1 than normal cells [75], the observed effect of Yarrow SFE on SREBF1 could
explain the specificity against tumor cells, being normal cells more protected.
In patients, together with SREBP1, FASN and SCD are also considered worse prognosis
markers. These genes are also diminished in MIA PaCa-2 cells after Yarrow SFE treatments.
In the same way, FASN has been shown to be upregulated in several cancers [16,84], includ-
ing pancreatic cancer [98,99]. High serum levels of FASN are associated with aggressiveness
[98,100] and resistance to the chemotherapeutic gemcitabine [101,102].
Fig 6. Yarrow SFE diminishes the growth of MIA PaCa-2 tumor xenograft in nude mice. (A) Tumor volume evolution of MIA PaCa-2 xenografts treated
with Yarrow SFE extract compared to non-treated control mice (corn oil). (B) Tumor weight, (C) Liver weight and (D) Total body weight quantification at the
end of the experiment. Data represents the mean ± S.E.M for 8 treated animals and 8 controls. Asterisks indicate statistical differences in treated with respect to
non-treated mice �p<0.05; ��p<0.01; ���p<0.001.
https://doi.org/10.1371/journal.pone.0214294.g006
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Conversely, FASN inhibition have been shown to decrease tumor growth and to drive apo-
ptotic cell death. These cytotoxic and cytostatic effects have been validated in ovarian, prostate
and pancreatic cancers [98,103,104]. In addition, FASN pharmacological blockage also syner-
gizes with 5-fluororacil [105] to enhance apoptosis activation [76,106]. In this sense, our results
match with previous ones, where Yarrow SFE extract could act as a FASN inhibitor.
Finally, regarding SCD, which catalyzes the rate limiting step in the production of monoun-
saturated fatty acids (MUFAs), whose levels are directly associated with replication rates in
cancer cells [107]. High levels of SCD have been described to increase cell proliferation and
survival in pancreatic tumors [107,108], and its inhibition has been shown to brake tumor
growth in lung, colorectal, osteosarcoma and breast tumors [65–67]. Thus, being considered
as a target for chemotherapy, SCD therapeutic inhibition affects tumor growth in several xeno-
graft models (prostate, kidney, gastric or ovarian tumor [68,69].
In the context of the use of phytochemicals for cancer treatment through a metabolic
approach, genistein and ginkgolic acid have already been demonstrated to induce cytotoxicity
by downregulating of SREBP1 [71,109]. Promising results have been obtained by luteolin,
which also targets FASN [76].
Herein, we demonstrate that Yarrow SFE inhibits SREBF1, FASN and SCD leading to less
accumulation of lipid droplets which also correlates with the inhibition of cell invasion. Fur-
ther studies are needed to better understand how Yarrow SFE could disrupt cell metabolism
and/or cell bioenergy through metabolomic approaches and cell bioenergetics flux analysis.
Importantly, we demonstrate the in vivo effect of Yarrow SFE inhibiting the tumor growth
of xenografts models, which seems to be mediated, at least partially, by the downregulation of
SREBP1.
In this sense, our data suggest that Yarrow SFE can be proposed as a complementary adju-
vant or nutritional complement in pancreatic cancer therapy.
Conclusions
Yarrow SFE decreases pancreatic cancer cell proliferation and invasion. We identify SREBF1
together with FASN and SCD, as molecular targets of Yarrow SFE. We also demonstrate the in
vivo effect of Yarrow SFE, which brakes tumor growth in a xenograft mouse model of pancre-
atic cancer, together with SREBF1 downregulation in the injected tumors. Our data suggest
that Yarrow SFE can be proposed as a complementary adjuvant or nutritional supplement in
pancreatic cancer therapy.
Supporting information
S1 Fig. Intracellular cholesterol levels. Relative intracellular cholesterol levels in human pan-
creatic cancer-derived MIA PaCa-2 (A) cells treated 48 hours two with different concentra-
tions of Yarrow SFE extract. Data represent the mean ± S.E.M of three independent
experiments each one performed in triplicate.
(TIF)
S2 Fig. Yarrow inhibits the expression of SREBF1 in SW620 colon cancer cells. Line.
mRNA relative expression of SREBF1 in SW620 cells treated 48 hours with different
Fig 7. Yarrow SFE diminishes pancreatic cancer cell proliferation in tumor xenografts and SREBF1 expression. (A)
Representative images of Ki-67 immunostaining and Ki-67 quantification at the end of the experiment. (B) SREBF1 expression
levels in tumors of Yarrow SFE treated mice compared to non-treated control mice (corn oil). Data represent the mean ± S.E.M
of five animals for the immunostaining and 8 animals for qPCR. Asterisks indicate statistical differences in treated animals
comparing with the control (corn oil) and �p<0.05.
https://doi.org/10.1371/journal.pone.0214294.g007
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concentrations of Yarrow extract compared to non-treated control cells (DMSO). Data repre-
sent the mean ± S.E.M of three independent experiment each one performed in triplicate.
Asterisks indicate statistical differences in treated cells with respect to the control (non-treated
cells) and �p<0.05��p<0.01; ���p<0.001.
(TIF)
Acknowledgments
We thank Dr. Jean-Baptiste Demoulin for having provided us the anti-SCD1 antibody.
Author Contributions
Conceptualization: Lamia Mouhid, Marta Go´mez de Cedro´n, Guillermo Reglero, Tiziana
Fornari, Ana Ramı´rez de Molina.
Formal analysis: Lamia Mouhid.
Investigation: Lamia Mouhid, Marta Go´mez de Cedro´n.
Methodology: Lamia Mouhid, Marta Go´mez de Cedro´n.
Resources: Elena Garcı´a-Carrascosa.
Supervision: Marta Go´mez de Cedro´n, Ana Ramı´rez de Molina.
Writing – original draft: Lamia Mouhid, Marta Go´mez de Cedro´n.
References
1. Michaud DS. Epidemiology of Pancreatic Cancer. Springer; 2017. pp. 471–487.
2. Gordon-Dseagu VL, Devesa S, Goggins M, Stolzenberg-Solomon R. No Title. Pancreat cancer Incid
trends Recent patterns overall by Histol type among US men women by racial/ethnic Gr Evid from Sur-
veillance, Epidemiol End Results Progr. 2017;
3. Surh Y-J. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003; 3: 768–780.
https://doi.org/10.1038/nrc1189 PMID: 14570043
4. Mouhid L, Corzo-Martı´nez M, Torres C, Va´zquez L, Reglero G, Fornari T, et al. Improving In Vivo Effi-
cacy of Bioactive Molecules: An Overview of Potentially Antitumor Phytochemicals and Currently
Available Lipid-Based Delivery Systems. J Oncol. 2017;2017.
5. Kotecha R, Takami A, Espinoza JL. Dietary phytochemicals and cancer chemoprevention: a review of
the clinical evidence. Oncotarget. 2016; 7: 52517–52529. https://doi.org/10.18632/oncotarget.9593
PMID: 27232756
6. Gonzalez-Vallinas M, Gonzalez-Castejon M, Rodriguez-Casado A, de Molina AR. Dietary phytochem-
icals in cancer prevention and therapy: a complementary approach with promising perspectives. Nutr
Rev. 2013; 71: 585–599. https://doi.org/10.1111/nure.12051 PMID: 24032363
7. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol. 2005; 100: 72–
79. https://doi.org/10.1016/j.jep.2005.05.011 PMID: 16009521
8. Ouyang L, Luo Y, Tian M, Zhang S, Lu R, Wang J, et al. Plant natural products: from traditional com-
pounds to new emerging drugs in cancer therapy. Cell Prolif. 2014; 47: 506–515. https://doi.org/10.
1111/cpr.12143 PMID: 25377084
9. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362: 1605–1617. https://doi.org/10.1056/
NEJMra0901557 PMID: 20427809
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–674.
https://doi.org/10.1016/j.cell.2011.02.013 PMID: 21376230
11. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic repro-
gramming fuels cell growth and proliferation. Cell Metab. 2008; 7: 11–20. https://doi.org/10.1016/j.
cmet.2007.10.002 PMID: 18177721
12. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical
opportunities. J Clin Invest. 2013; 123: 3678–3684. https://doi.org/10.1172/JCI69600 PMID:
23999442
Yarrow extract as a supplement in pancreatic cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0214294 March 26, 2019 16 / 21
13. Blum R, Kloog Y. Metabolism addiction in pancreatic cancer. Cell Death Dis. 2014; 5: e1065. https://
doi.org/10.1038/cddis.2014.38 PMID: 24556680
14. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem
Sci. 2010; 35: 427–433. https://doi.org/10.1016/j.tibs.2010.05.003 PMID: 20570523
15. Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in
neoplastic tissue slices in vitro. Cancer Res. 1953; 13: 27–29. PMID: 13032945
16. Currie E, Schulze A, Zechner R, Walther TC, Farese R V. Cellular fatty acid metabolism and cancer.
Cell Metab. 2013; 18: 153–161. https://doi.org/10.1016/j.cmet.2013.05.017 PMID: 23791484
17. Vargas T, Moreno-Rubio J, Herranz J, Cejas P, Molina S, Gonzalez-Vallinas M, et al. ColoLipidGene:
signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients.
Oncotarget. 2015; 6: 7348–7363. https://doi.org/10.18632/oncotarget.3130 PMID: 25749516
18. Fan TWM, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, et al. Altered regulation of meta-
bolic pathways in human lung cancer discerned by 13 C stable isotope-resolved metabolomics
(SIRM). Mol Cancer. 2009; 8: 41. https://doi.org/10.1186/1476-4598-8-41 PMID: 19558692
19. Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Onco-
genesis. 2016; 5: e189. https://doi.org/10.1038/oncsis.2015.49 PMID: 26807644
20. Peck B, Schulze A. Lipid desaturation–the next step in targeting lipogenesis in cancer? FEBS J. 2016;
283: 2767–2778. https://doi.org/10.1111/febs.13681 PMID: 26881388
21. Garcı´a-Risco MR, Mouhid L, Salas-Pe´rez L, Lo´pez-Padilla A, Santoyo S, Jaime L, et al. Biological
Activities of Asteraceae (Achillea millefolium and Calendula officinalis) and Lamiaceae (Melissa offici-
nalis and Origanum majorana) Plant Extracts. Plant Foods Hum Nutr. 2017; 72: 96–102. https://doi.
org/10.1007/s11130-016-0596-8 PMID: 28101823
22. Mouhid L, de Cedro´n MG, Vargas T, Garcı´a-Carrascosa E, Muñoz NH, Garcı´a-Risco MR, et al. Identi-
fication of antitumoral agents against human pancreatic cancer cells from Asteraceae and Lamiaceae
plant extracts. 2018;BMC Comple. https://doi.org/10.1186/s12906-018-2322-6 PMID: 30223811
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR
and the 2− ΔΔCT method. methods. 2001; 25: 402–408. https://doi.org/10.1006/meth.2001.1262
PMID: 11846609
24. Demoulin JB, Ericsson J, Kallin A, Rorsman C, Ronnstrand L, Heldin CH. Platelet-derived growth fac-
tor stimulates membrane lipid synthesis through activation of phosphatidylinositol 3-kinase and sterol
regulatory element-binding proteins. J Biol Chem. 2004; 279: 35392–35402. https://doi.org/10.1074/
jbc.M405924200 PMID: 15213220
25. Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, et al. Arginine deiminase as a
novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer
Res. 2009; 69: 700–708. https://doi.org/10.1158/0008-5472.CAN-08-3157 PMID: 19147587
26. Phillips MM, Sheaff MT, Szlosarek PW. Targeting arginine-dependent cancers with arginine-degrad-
ing enzymes: opportunities and challenges. Cancer Res Treat. 2013; 45: 251–262. https://doi.org/10.
4143/crt.2013.45.4.251 PMID: 24453997
27. Sullivan LB, Gui DY, Heiden MG Vander. Altered metabolite levels in cancer: implications for tumour
biology and cancer therapy. Nat Rev Cancer. 2016; 16: 680–693. https://doi.org/10.1038/nrc.2016.85
PMID: 27658530
28. Bowles TL, Kim R, Galante J, Parsons CM, Virudachalam S, Kung H, et al. Pancreatic cancer cell
lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deimi-
nase. Int J cancer. 2008; 123: 1950–1955. https://doi.org/10.1002/ijc.23723 PMID: 18661517
29. Liu J, Ma J, Wu Z, Li W, Zhang D, Han L, et al. Arginine deiminase augments the chemosensitivity of
argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB
signaling. BMC Cancer. 2014; 14: 1. https://doi.org/10.1186/1471-2407-14-1
30. Qiu F, Huang J, Sui M. Targeting arginine metabolism pathway to treat arginine-dependent cancers.
Cancer Lett. 2015; 364: 1–7. https://doi.org/10.1016/j.canlet.2015.04.020 PMID: 25917076
31. Kolla V, Zhuang T, Higashi M, Naraparaju K, Brodeur GM. Role of CHD5 in human cancers: 10 years
later. Cancer Res. 2014; 74: 652–658. https://doi.org/10.1158/0008-5472.CAN-13-3056 PMID:
24419087
32. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, et al. CHD5 is a tumor suppressor at
human 1p36. Cell. 2007; 128: 459–475. https://doi.org/10.1016/j.cell.2006.11.052 PMID: 17289567
33. Zhao R, Yan Q, Lv J, Huang H, Zheng W, Zhang B, et al. CHD5, a tumor suppressor that is epigeneti-
cally silenced in lung cancer. Lung cancer. 2012; 76: 324–331. https://doi.org/10.1016/j.lungcan.2011.
11.019 PMID: 22186629
34. Hall WA, Petrova A V, Colbert LE, Hardy CW, Fisher SB, Saka B, et al. Low CHD5 expression acti-
vates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy
Yarrow extract as a supplement in pancreatic cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0214294 March 26, 2019 17 / 21
for resected pancreatic cancer. Oncogene. 2014; 33: 5450–5456. https://doi.org/10.1038/onc.2013.
488 PMID: 24276239
35. Zhang R, Thamm DH, Misra V. The effect of Zhangfei/CREBZF on cell growth, differentiation, apopto-
sis, migration, and the unfolded protein response in several canine osteosarcoma cell lines. BMC Vet
Res. 2015; 11: 1. https://doi.org/10.1186/s12917-014-0312-6 PMID: 25582057
36. Lo´pez-Mateo I, Villaronga MA´ , Llanos S, Belandia B. The transcription factor CREBZF is a novel posi-
tive regulator of p53. Cell Cycle. 2012; 11: 3887–3895. https://doi.org/10.4161/cc.22133 PMID:
22983008
37. Rozenblatt-Rosen O, Nagaike T, Francis JM, Kaneko S, Glatt KA, Hughes CM, et al. The tumor sup-
pressor Cdc73 functionally associates with CPSF and CstF 3’ mRNA processing factors. Proc Natl
Acad Sci U S A. 2009; 106: 755–760. https://doi.org/10.1073/pnas.0812023106 PMID: 19136632
38. Rather MI, Nagashri MN, Swamy SS, Gopinath KS, Kumar A. Oncogenic microRNA-155 down-regu-
lates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implica-
tions for cancer therapeutics. J Biol Chem. 2013; 288: 608–618. https://doi.org/10.1074/jbc.M112.
425736 PMID: 23166327
39. Kirschner RD, Rother K, Mu¨ller GA, Engeland K. The retinal dehydrogenase/reductase retSDR1/
DHRS3 gene is activated by p53 and p63 but not by mutants derived from tumors or EEC/ADULT mal-
formation syndromes. Cell Cycle. 2010; 9: 2177–2188. https://doi.org/10.4161/cc.9.11.11844 PMID:
20543567
40. Deisenroth C, Itahana Y, Tollini L, Jin A, Zhang Y. p53-Inducible DHRS3 is an endoplasmic reticulum
protein associated with lipid droplet accumulation. J Biol Chem. 2011; 286: 28343–28356. https://doi.
org/10.1074/jbc.M111.254227 PMID: 21659514
41. Yan W-H. HLA-G expression in cancers: potential role in diagnosis, prognosis and therapy. Endocrine,
Metab Immune Disord Targets (Formerly Curr Drug Targets-Immune, Endocr Metab Disord. 2011; 11:
76–89.
42. Cao M, Yie S, Liu J, Ye SR, Xia D, Gao E. Plasma soluble HLA-G is a potential biomarker for diagnosis
of colorectal, gastric, esophageal and lung cancer. Tissue Antigens. 2011; 78: 120–128. https://doi.
org/10.1111/j.1399-0039.2011.01716.x PMID: 21726203
43. Nazemalhosseini-Mojarad E, Kuppen PJ, Zali MR. Human Leukocyte antigen-G (HLA-G) and gastro-
intestinal malignancy. Gastroenterol Hepatol from bed to bench. 2014; 7: 79–81.
44. Hansel DE, Rahman A, Wilentz RE, Shih I, McMaster MT, Yeo CJ, et al. HLA-G upregulation in pre-
malignant and malignant lesions of the gastrointestinal tract. Int J Gastrointest Cancer. 2005; 35: 15–
23. PMID: 15722570
45. Xu Y-F, Lu Y, Cheng H, Jiang J, Xu J, Long J, et al. High expression of human leukocyte antigen-G is
associated with a poor prognosis in patients with PDAC. Curr Mol Med. 2015; 15: 360–367. PMID:
25829020
46. Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 2007; 67:
3496–3499. 67/8/3496 [pii] https://doi.org/10.1158/0008-5472.CAN-07-0325 PMID: 17440054
47. Yang Z, Zhuang L, Szatmary P, Wen L, Sun H, Lu Y, et al. Upregulation of heat shock proteins
(HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor out-
comes from HBV-related early-stage hepatocellular carcinoma. Int J Med Sci. 2015; 12: 256–263.
https://doi.org/10.7150/ijms.10735 PMID: 25798051
48. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer.
2007; 7: 834–846. https://doi.org/10.1038/nrc2256 PMID: 17957189
49. Uckun FM, Qazi S, Ozer Z, Garner AL, Pitt J, Ma H, et al. Inducing apoptosis in chemotherapy-resis-
tant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-
apoptotic unfolded protein response signalling network. Br J Haematol. 2011; 153: 741–752. https://
doi.org/10.1111/j.1365-2141.2011.08671.x PMID: 21517817
50. Zhe-Yu N, Qiao-Fei L, Meng-Yi W, Li Z, Lu-Tian Y, Quan L, et al. Changes in the Expression of Glu-
cose-regulated Protein 78 in the Occurrence and Progression of Pancreatic Cancer in Mouse Models.
Zhongguo yi xue ke xue yuan xue baoActa Acad Med Sin. 2015; 37: 259–263. https://doi.org/10.3881/
j.issn.1000-503X.2015.03.002 PMID: 26149133
51. Yuan XP, Dong M, Li X, Zhou JP. GRP78 promotes the invasion of pancreatic cancer cells by FAK
and JNK. Mol Cell Biochem. 2015; 398: 55–62. https://doi.org/10.1007/s11010-014-2204-2 PMID:
25218495
52. Djidja M-C, Claude E, Snel MF, Scriven P, Francese S, Carolan V, et al. MALDI-ion mobility separa-
tion-mass spectrometry imaging of glucose-regulated protein 78 kDa (Grp78) in human formalin-fixed,
paraffin-embedded pancreatic adenocarcinoma tissue sections. J Proteome Res. 2009; 8: 4876–
4884. https://doi.org/10.1021/pr900522m PMID: 19673544
Yarrow extract as a supplement in pancreatic cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0214294 March 26, 2019 18 / 21
53. Kammerer S, Roth RB, Reneland R, Marnellos G, Hoyal CR, Markward NJ, et al. Large-scale associa-
tion study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Cancer Res.
2004; 64: 8906–8910. 64/24/8906 [pii] https://doi.org/10.1158/0008-5472.CAN-04-1788 PMID:
15604251
54. Maruya SI, Myers JN, Weber RS, Rosenthal DI, Lotan R, El-Naggar AK. ICAM-5 (telencephalin) gene
expression in head and neck squamous carcinoma tumorigenesis and perineural invasion! Oral
Oncol. 2005; 41: 580–588. https://doi.org/10.1016/j.oraloncology.2005.01.002 PMID: 15975520
55. Gunduz M, Beder LB, Gunduz E, Nagatsuka H, Fukushima K, Pehlivan D, et al. Downregulation of
ING3 mRNA expression predicts poor prognosis in head and neck cancer. Cancer Sci. 2008; 99: 531–
538. https://doi.org/10.1111/j.1349-7006.2007.00708.x PMID: 18081876
56. Doyon Y, Cayrou C, Ullah M, Landry A-J, Coˆte´ V, Selleck W, et al. ING tumor suppressor proteins are
critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell.
2006; 21: 51–64. https://doi.org/10.1016/j.molcel.2005.12.007 PMID: 16387653
57. Zhang M, Truscott J, Davie J. Loss of MEF2D expression inhibits differentiation and contributes to
oncogenesis in rhabdomyosarcoma cells. Mol Cancer. 2013; 12: 1. https://doi.org/10.1186/1476-
4598-12-1
58. Ma L, Liu J, Liu L, Duan G, Wang Q, Xu Y, et al. Overexpression of the transcription factor MEF2D in
hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes. Cancer
Res. 2014; 74: 1452–1462. https://doi.org/10.1158/0008-5472.CAN-13-2171 PMID: 24390737
59. Song L, Li D, Zhao Y, Gu Y, Zhao D, Li X, et al. miR-218 suppressed the growth of lung carcinoma by
reducing MEF2D expression. Tumor Biol. 2016; 37: 2891–2900.
60. Turk CM, Fagan-Solis KD, Williams KE, Gozgit JM, Smith-Schneider S, Marconi SA, et al. Paralem-
min-1 is over-expressed in estrogen-receptor positive breast cancers. Cancer Cell Int. 2012; 12: 1.
https://doi.org/10.1186/1475-2867-12-1
61. Albrecht I, Bieri R, Leu A, Granacher P, Hagmann J, Kilimann MW, et al. Paralemmin-1 is expressed
in lymphatic endothelial cells and modulates cell migration, cell maturation and tumor lymphangiogen-
esis. Angiogenesis. 2013; 16: 795–807. https://doi.org/10.1007/s10456-013-9356-7 PMID: 23709172
62. Subramani D, Alahari SK. Integrin-mediated function of Rab GTPases in cancer progression. Mol
Cancer. 2010; 9: 1. https://doi.org/10.1186/1476-4598-9-1
63. Kloth JN, Gorter A, Fleuren GJ, Oosting J, Uljee S, Haar N Ter, et al. Elevated expression of SerpinA1
and SerpinA3 in HLA-positive cervical carcinoma. J Pathol. 2008; 215: 222–230. https://doi.org/10.
1002/path.2347 PMID: 18438953
64. Dimberg J, Stro¨m K, Lo¨fgren S, Zar N, Hugander A, Matussek A. Expression of the serine protease
inhibitor serpinA3 in human colorectal adenocarcinomas. Oncol Lett. 2011; 2: 413–418. https://doi.
org/10.3892/ol.2011.280 PMID: 22866096
65. Choi KY, Cho YJ, Kim JS, Ahn Y-H, Hong SH. SHC1 sensitizes cancer cells to the 8-Cl-cAMP treat-
ment. Biochem Biophys Res Commun. 2015; 463: 673–678. https://doi.org/10.1016/j.bbrc.2015.05.
123 PMID: 26043699
66. Hamada S, Masamune A, Miura S, Satoh K, Shimosegawa T. MiR-365 induces gemcitabine resis-
tance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator
BAX. Cell Signal. 2014; 26: 179–185. https://doi.org/10.1016/j.cellsig.2013.11.003 PMID: 24216611
67. Kuranami S, Yokobori T, Mogi A, Altan B, Yajima T, Onozato R, et al. Src kinase-associated phospho-
protein2 expression is associated with poor prognosis in non-small cell lung cancer. Anticancer Res.
2015; 35: 2411–2415. 35/4/2411 [pii] PMID: 25862907
68. Tanaka M, Shimamura S, Kuriyama S, Maeda D, Goto A, Aiba N. SKAP2 Promotes Podosome For-
mation to Facilitate Tumor-Associated Macrophage Infiltration and Metastatic Progression. Cancer
Res. 2016; 76: 358–369. https://doi.org/10.1158/0008-5472.CAN-15-1879 PMID: 26577701
69. Harada T, Chelala C, Bhakta V, Chaplin T, Caulee K, Baril P, et al. Genome-wide DNA copy number
analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene.
2008; 27: 1951–1960. https://doi.org/10.1038/sj.onc.1210832 PMID: 17952125
70. Huang WC, Li X, Liu J, Lin J, Chung LW. Activation of androgen receptor, lipogenesis, and oxidative
stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer
cells. Mol Cancer Res. 2012; 10: 133–142. https://doi.org/10.1158/1541-7786.MCR-11-0206 PMID:
22064655
71. Eberhard Y, Gronda M, Hurren R, Datti A, MacLean N, Ketela T, et al. Inhibition of SREBP1 sensitizes
cells to death ligands. Oncotarget. 2011; 2: 186–196. https://doi.org/10.18632/oncotarget.239 PMID:
21406729
Yarrow extract as a supplement in pancreatic cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0214294 March 26, 2019 19 / 21
72. Lin L, Zheng X, Qiu C, Dongol S, Lv Q, Jiang J, et al. SIRT1 promotes endometrial tumor growth by tar-
geting SREBP1 and lipogenesis. Oncol Rep. 2014; 32: 2831–2835. https://doi.org/10.3892/or.2014.
3521 PMID: 25270091
73. Li W, Tai Y, Zhou J, Gu W, Bai Z, Zhou T, et al. Repression of endometrial tumor growth by targeting
SREBP1 and lipogenesis. Cell cycle. 2012; 11: 2348–2358. https://doi.org/10.4161/cc.20811 PMID:
22672904
74. Li C, Yang W, Zhang J, Zheng X, Yao Y, Tu K, et al. SREBP-1 has a prognostic role and contributes to
invasion and metastasis in human hepatocellular carcinoma. Int J Mol Sci. 2014; 15: 7124–7138.
https://doi.org/10.3390/ijms15057124 PMID: 24776759
75. Sun Y, He W, Luo M, Zhou Y, Chang G, Ren W, et al. SREBP1 regulates tumorigenesis and prognosis
of pancreatic cancer through targeting lipid metabolism. Tumor Biol. 2015; 1–9. https://doi.org/10.
1007/s13277-015-3047-5 PMID: 25589463
76. Li J, Gu D, Lee SSY, Song B, Bandyopadhyay S, Chen S, et al. Abrogating cholesterol esterification
suppresses growth and metastasis of pancreatic cancer. Oncogene. 2016;
77. Xing Y, Meng Q, Chen X, Zhao Y, Liu W, Hu J, et al. TRIM44 promotes proliferation and metastasis in
nonsmall cell lung cancer via mTOR signaling pathway. Oncotarget. 2016; https://doi.org/10.18632/
oncotarget.8586 PMID: 27058415
78. Kashimoto K, Komatsu S, Ichikawa D, Arita T, Konishi H, Nagata H, et al. Overexpression of TRIM44
contributes to malignant outcome in gastric carcinoma. Cancer Sci. 2012; 103: 2021–2026. https://doi.
org/10.1111/j.1349-7006.2012.02407.x PMID: 22862969
79. Ong CA, Shannon NB, Ross-Innes CS, O’Donovan M, Rueda OM, Hu DE, et al. Amplification of
TRIM44: pairing a prognostic target with potential therapeutic strategy. J Natl Cancer Inst. 2014; 106:
10.1093/jnci/dju050. https://doi.org/10.1093/jnci/dju050 PMID: 24777112
80. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and
fatty acid synthesis in the liver. J Clin Invest. 2002; 109: 1125–1131. https://doi.org/10.1172/JCI15593
PMID: 11994399
81. Eberle´ D, Hegarty B, Bossard P, Ferre´ P, Foufelle F. SREBP transcription factors: master regulators
of lipid homeostasis. Biochimie. 2004; 86: 839–848. https://doi.org/10.1016/j.biochi.2004.09.018
PMID: 15589694
82. Guo D, Bell EH, Mischel P, Chakravarti A. Targeting SREBP-1-driven lipid metabolism to treat cancer.
Curr Pharm Des. 2014; 20: 2619–2626. PMID: 23859617
83. Cruz PM, Mo H, McConathy WJ, Sabnis N, Lacko AG. The role of cholesterol metabolism and choles-
terol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics.
Front Pharmacol. 2013; 4: 119. https://doi.org/10.3389/fphar.2013.00119 PMID: 24093019
84. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat
Rev. 2007; 7: 763.
85. Fleischmann M, Iynedjian PB. Regulation of sterol regulatory-element binding protein 1 gene expres-
sion in liver: role of insulin and protein kinase B/cAkt. Biochem J. 2000; 349: 13–17. PMID: 10861205
86. Dang C V. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer
Res. 2010; 70: 859–862. https://doi.org/10.1158/0008-5472.CAN-09-3556 PMID: 20086171
87. Yang Y, Liu H, Li Z, Zhao Z, Yip-Schneider M, Fan Q, et al. Role of fatty acid synthase in gemcitabine
and radiation resistance of pancreatic cancers. Int J Biochem Mol Biol. 2011; 2: 89–98. PMID:
21331354
88. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, et al. Survivin as a radioresis-
tance factor in pancreatic cancer. Cancer Sci. 2000; 91: 1204–1209.
89. Long XH, Mao JH, Peng AF, Zhou Y, Huang SH, Liu ZL. Tumor suppressive microRNA-424 inhibits
osteosarcoma cell migration and invasion via targeting fatty acid synthase. Exp Ther Med. 2013; 5:
1048–1052. https://doi.org/10.3892/etm.2013.959 PMID: 23599729
90. Walter K, Hong SM, Nyhan S, Canto M, Fedarko N, Klein A, et al. Serum fatty acid synthase as a
marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2380–2385. https://doi.
org/10.1158/1055-9965.EPI-09-0144 PMID: 19723916
91. Zhang Y-J, Gan R-Y, Li S, Zhou Y, Li A-N, Xu D-P, et al. Antioxidant phytochemicals for the prevention
and treatment of chronic diseases. Molecules. 2015; 20: 21138–21156. https://doi.org/10.3390/
molecules201219753 PMID: 26633317
92. Zhang A, Sun H, Wang X. Recent advances in natural products from plants for treatment of liver dis-
eases. Eur J Med Chem. 2013; 63: 570–577. https://doi.org/10.1016/j.ejmech.2012.12.062 PMID:
23567947
Yarrow extract as a supplement in pancreatic cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0214294 March 26, 2019 20 / 21
93. Yin T, Wei H, Gou S, Shi P, Yang Z, Zhao G, et al. Cancer stem-like cells enriched in panc-1 spheres
possess increased migration ability and resistance to gemcitabine. Int J Mol Sci. 2011; 12: 1595–
1604. https://doi.org/10.3390/ijms12031595 PMID: 21673909
94. Choi WI, Jeon BN, Park H, Yoo JY, Kim YS, Koh DI, et al. Proto-oncogene FBI-1 (Pokemon) and
SREBP-1 synergistically activate transcription of fatty-acid synthase gene (FASN). J Biol Chem. 2008;
283: 29341–29354. https://doi.org/10.1074/jbc.M802477200 PMID: 18682402
95. Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, Ferber EC, et al. Sterol regulatory element binding
protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer Metab.
2013; 1: 3. https://doi.org/10.1186/2049-3002-1-3 PMID: 24280005
96. Oh SY, Park SK, Kim JW, Ahn YH, Park SW, Kim KS. Acetyl-CoA carboxylase beta gene is regulated
by sterol regulatory element-binding protein-1 in liver. J Biol Chem. 2003; 278: 28410–28417. https://
doi.org/10.1074/jbc.M300553200 PMID: 12764144
97. Sekar S, Gopalakrishnan V, Taghibiglou C. Sterol regulatory element-binding protein 1 inhibitors
decrease pancreatic cancer cell viability and proliferation. Biochem Biophys Res Commun. 2017; 488:
136–140. https://doi.org/10.1016/j.bbrc.2017.05.023 PMID: 28483521
98. Swierczynski J, Hebanowska A, Sledzinski T. Role of abnormal lipid metabolism in development, pro-
gression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol. 2014; 20: 2279–2303.
https://doi.org/10.3748/wjg.v20.i9.2279 PMID: 24605027
99. Falasca M, Kim M, Casari I. Pancreatic cancer: current research and future directions. Biochim Bio-
phys Acta (BBA)-Reviews Cancer. 2016; 1865: 123–132.
100. Yabushita S, Fukamachi K, Kikuchi F, Ozaki M, Miyata K, Sukata T, et al. Twenty-one proteins up-reg-
ulated in human H-ras oncogene transgenic rat pancreas cancers are up-regulated in human pan-
creas cancer. Pancreas. 2013; 42: 1034–1039. https://doi.org/10.1097/MPA.0b013e3182883624
PMID: 23648844
101. Yang Y, Liu H, Li Z, Zhao Z, Yip-Schneider M, Fan Q, et al. Role of fatty acid synthase in gemcitabine
and radiation resistance of pancreatic cancers. Int J Biochem Mol Biol. 2011; 2: 89–98. PMID:
21331354
102. Wu X, Qin L, Fako V, Zhang J-T. Molecular mechanisms of fatty acid synthase (FASN)-mediated
resistance to anti-cancer treatments. Adv Biol Regul. 2014; 54: 214–221. https://doi.org/10.1016/j.
jbior.2013.09.004 PMID: 24080588
103. Kridel SJ, Lowther WT, IV CWP. Fatty acid synthase inhibitors: new directions for oncology. Expert
Opin Investig Drugs. 2007; 16: 1817–1829. https://doi.org/10.1517/13543784.16.11.1817 PMID:
17970640
104. Li JN, Gorospe M, Chrest FJ, Kumaravel TS, Evans MK, Han WF, et al. Pharmacological inhibition of
fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer
Res. 2001; 61: 1493–1499. PMID: 11245456
105. Vazquez-Martin A, Ropero S, Brunet J, Colomer R, Menendez JA. Inhibition of Fatty Acid Synthase
(FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. Oncol Rep.
2007; 18: 973–980. PMID: 17786362
106. Zecchin KG, Rossato FA, Raposo HF, Melo DR, Alberici LC, Oliveira HCF, et al. Inhibition of fatty acid
synthase in melanoma cells activates the intrinsic pathway of apoptosis. Lab Investig. 2011; 91: 232–
240. https://doi.org/10.1038/labinvest.2010.157 PMID: 20805790
107. Igal RA. Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, pro-
grammed cell death and transformation to cancer. Carcinogenesis. 2010; 31: 1509–1515. https://doi.
org/10.1093/carcin/bgq131 PMID: 20595235
108. Maca´sˇek J, Vecka M, Zˇ a´k A, Urba´nek M, Krechler T, Petruzˇelka L, et al. Plasma fatty acid composition
in patients with pancreatic cancer: correlations to clinical parameters. Nutr Cancer. 2012; 64: 946–
955. https://doi.org/10.1080/01635581.2012.716138 PMID: 23061902
109. Nie L-Y, Lu Q-T, Li W-H, Yang N, Dongol S, Zhang X, et al. Sterol regulatory element-binding protein 1
is required for ovarian tumor growth. Oncol Rep. 2013; 30: 1346–1354. https://doi.org/10.3892/or.
2013.2575 PMID: 23818099
Yarrow extract as a supplement in pancreatic cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0214294 March 26, 2019 21 / 21
